Imago BioSciences begins enrolment for Phase I/II study of IMG-7289 to treat AML and MDS

US-based pharmaceutical company Imago BioSciences has begun enrolment for its Phase I/II study of IMG-7289 to treat high-risk acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news